Shasun Pharmaceuticals is trading higher by 5% to Rs 143, extending its previous day’s 6% rally, after announcing that it has acquired the global rights to develop and commercialise Ibuprofen's 12-hour extended release tablets from the US-based ScolrPharma and the global rights of analgesics Nuprin for an undisclosed sum.
The acquisition also includes the controlled release technology of Ibuprofen 12-hour extended release OTC, Shashun Pharmaceuticals said in a statement on the Bombay Stock Exchange (BSE).
"The acquisition complements Shasun's strategy to expand its range of non-steroidal anti-inflammatory drug (NSAIDS) products through novel, safe and efficacious technologies, including applications across its Ibuprofen franchise," the company said.
The stock opened at Rs 142 and touched a 52-week high of Rs 144 on the BSE. A combined 1.34 million shares changed hands on the counter so far on the BSE and NSE.
The acquisition also includes the controlled release technology of Ibuprofen 12-hour extended release OTC, Shashun Pharmaceuticals said in a statement on the Bombay Stock Exchange (BSE).
"The acquisition complements Shasun's strategy to expand its range of non-steroidal anti-inflammatory drug (NSAIDS) products through novel, safe and efficacious technologies, including applications across its Ibuprofen franchise," the company said.
The stock opened at Rs 142 and touched a 52-week high of Rs 144 on the BSE. A combined 1.34 million shares changed hands on the counter so far on the BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%